ERBB2 and breast cancer: Through analyzing the epidemiological and clinicopathological trends of breast cancer in China during the 20 years, we found a shift toward older age, an increasing proportion of early diagnosis, and the predominant trend of Luminal B (HER2-negative) in this study.